Page 72 - Read Online

Page 26 of 29 Novati et al. Ageing Neur Dis 2022;2:17 https://dx.doi.org/10.20517/and.2022.19

non-motoric behavioural impairments. Genes Brain Behav 2010;9:305-17. DOI PubMed
208. Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers 2015;1:15005. DOI PubMed
209. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive
neurological phenotype in transgenic mice. Cell 1996;87:493-506. DOI PubMed
210. Nguyen HP, Kobbe P, Rahne H, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for
Huntington’s disease. Hum Mol Genet 2006;15:3177-94. DOI PubMed
211. Bode FJ, Stephan M, Suhling H, et al. Sex differences in a transgenic rat model of Huntington’s disease: decreased 17beta-estradiol
levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 2008;17:2595-609. DOI PubMed
212. Kurat S, Heinrich P, Molnar-Kasza A, Loeffler T, Flunkert S, Hutter-Paier B. Homozygosity of BACHD rats not only causes strong
behavioral deficits in young female rats but also a reduced breeding success. Brain Res 2021;1761:147396. DOI
213. Abada YS, Nguyen HP, Schreiber R, Ellenbroek B. Assessment of motor function, sensory motor gating and recognition memory in a
novel BACHD transgenic rat model for Huntington disease. PLoS One 2013;8:e68584. DOI PubMed PMC
214. Novati A, Manfré G, Flunkert S, et al. Validation of behavioral phenotypes in the BACHD rat model. Behav Brain Res
2020;393:112783. DOI PubMed
215. Manfré G, Clemensson EKH, Kyriakou EI, et al. The BACHD rat model of Huntington disease shows specific deficits in a test
battery of motor function. Front Behav Neurosci 2017;11:218. DOI PubMed PMC
216. Urbach YK, Raber KA, Canneva F, et al. Automated phenotyping and advanced data mining exemplified in rats transgenic for
Huntington’s disease. J Neurosci Methods 2014;234:38-53. DOI PubMed
217. Faure A, Höhn S, Von Hörsten S, et al. Altered emotional and motivational processing in the transgenic rat model for Huntington’s
disease. Neurobiol Learn Mem 2011;95:92-101. DOI PubMed
218. Ortiz AN, Osterhaus GL, Lauderdale K, et al. Motor function and dopamine release measurements in transgenic Huntington’s disease
model rats. Brain Res 2012;1450:148-56. DOI PubMed PMC
219. Cao C, Temel Y, Blokland A, et al. Progressive deterioration of reaction time performance and choreiform symptoms in a new
Huntington’s disease transgenic ratmodel. Behav Brain Res 2006;170:257-61. DOI PubMed
220. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle
response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 1995;58:192-200. DOI PubMed PMC
221. Höhn S, Dallérac G, Faure A, et al. Behavioral and in vivo electrophysiological evidence for presymptomatic alteration of
prefrontostriatal processing in the transgenic rat model for Huntington disease. J Neurosci 2011;31:8986-97. DOI PubMed PMC
222. Goh AM, Wibawa P, Loi SM, Walterfang M, Velakoulis D, Looi JC. Huntington’s disease: neuropsychiatric manifestations of
Huntington’s disease. Australas Psychiatry 2018;26:366-75. DOI PubMed
223. Paulsen JS, Miller AC, Hayes T, Shaw E. Cognitive and behavioral changes in Huntington disease before diagnosis. Huntington
disease. Elsevier; 2017. p. 69-91. DOI PubMed
224. Bora E, Velakoulis D, Walterfang M. Social cognition in Huntington’s disease: a meta-analysis. Behav Brain Res 2016;297:131-40.
DOI PubMed
225. Herben-Dekker M, van Oostrom JC, Roos RA, et al. Striatal metabolism and psychomotor speed as predictors of motor onset in
Huntington’s disease. J Neurol 2014;261:1387-97. DOI PubMed
226. Say MJ, Jones R, Scahill RI, et al; TRACK-HD Investigators. Visuomotor integration deficits precede clinical onset in Huntington’s
disease. Neuropsychologia 2011;49:264-70. DOI PubMed
227. You SC, Geschwind MD, Sha SJ, et al. Executive functions in premanifest Huntington’s disease. Mov Disord 2014;29:405-9. DOI
PubMed PMC
228. Zeef DH, Vlamings R, Lim LW, et al. Motor and non-motor behaviour in experimental Huntington’s disease. Behav Brain Res
2012;226:435-9. DOI PubMed
229. Lamirault C, Nguyen HP, Doyère V, El Massioui N. Age-related alteration of emotional regulation in the BACHD rat model of
Huntington disease. Genes Brain Behav 2020;19:e12633. DOI PubMed
230. Lamirault C, Yu-Taeger L, Doyère V, Riess O, Nguyen HP, El Massioui N. Altered reactivity of central amygdala to GABA R
A
antagonist in the BACHD rat model of Huntington disease. Neuropharmacology 2017;123:136-47. DOI PubMed
231. Aharony I, Ehrnhoefer DE, Shruster A, et al. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant
Huntingtin-induced motor and behavioral deficits. Hum Mol Genet 2015;24:2604-14. DOI PubMed PMC
232. Chiu CT, Liu G, Leeds P, Chuang DM. Combined treatment with the mood stabilizers lithium and valproate produces multiple
beneficial effects in transgenic mouse models of Huntington’s disease. Neuropsychopharmacology 2011;36:2406-21. DOI PubMed
PMC
233. Hult Lundh S, Nilsson N, Soylu R, Kirik D, Petersén Å. Hypothalamic expression of mutant huntingtin contributes to the
development of depressive-like behavior in the BAC transgenic mouse model of Huntington’s disease. Hum Mol Genet
2013;22:3485-97. DOI
234. Pouladi MA, Stanek LM, Xie Y, et al. Marked differences in neurochemistry and aggregates despite similar behavioural and
neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 2012;21:2219-32.
DOI PubMed
235. Zlebnik NE, Gildish I, Sesia T, et al. Motivational impairment is accompanied by corticoaccumbal dysfunction in the BACHD-Tg5
rat model of Huntington’s disease. Cereb Cortex 2019;29:4763-74. DOI PubMed PMC